Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2013

Prexton Licenses Domain's Parkinson's Disease Drug

  • Domain Therapeutics granted Prexton Therapeutics, a spin-off company of Merck Serono, an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease. Under the agreement, Prexton will progress the mGluR4 PAM drug candidates into clinical development.

    The chemical series was previously developed through a licensing and collaboration agreement signed between Domain and Merck Serono in January 2011 to focus on research efforts on certain diseases such as multiple sclerosis, cancer, and immune-mediated diseases.

    Under the agreement with Merck, Domain contributed optimized compounds developed from its chemical series and received €2 million in up-front payment and research funding, and was eligible for up to €132 million in milestones for the first two products.

    mGluR4 is a glutamate receptor, member of the GPCR family. Allosteric modulation of mGluR4 receptors is thought to exert regulatory activity on glutamate-mediated neurotransmission.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »